Annals of Hematology

, Volume 84, Supplement 1, pp 9–17

An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients

  • P. W. Wijermans
  • M. Lübbert
  • G. Verhoef
  • V. Klimek
  • A. Bosly
Original Article

DOI: 10.1007/s00277-005-0012-1

Cite this article as:
Wijermans, P.W., Lübbert, M., Verhoef, G. et al. Ann Hematol (2005) 84(Suppl 1): 9. doi:10.1007/s00277-005-0012-1


During the last 10 years, three European phase II studies were performed to investigate the treatment of elderly patients with myelodysplastic syndrome (MDS) with low-dose 5-aza-2′-deoxycytidine (decitabine, DAC). All these European trial data were reviewed on the basis of the International Prognostic Scoring System (IPSS) risk criteria and the response criteria as recently published by an international working group. To investigate the results in a larger cohort of patients and to determine risk factors, all data were pooled with some observations from the PCH 95-06 US phase II study. The response rate in the 177 patients evaluated (median age 70 years) was 49%. The median response duration was 36 weeks, and the median survival was 15 months. Analysis of the data according to sex, age, French–American–British classification, percentage of blasts in the bone marrow, IPSS risk group, lactate dehydrogenase and cytogenetics did not reveal any factor predictive of response. Overall, 69% of patients benefited, including those with stable disease during therapy. Response duration was significantly shorter with increasing risk (according to the IPSS classification). Haemoglobin level and neutrophil count showed an inverse correlation to the IPSS classification. Univariate analysis showed a significantly inferior survival for elderly patients (>75 years of age) and for those with high levels of serum lactate dehydrogenase (LDH) (more than two times the normal values). Patients with high-risk cytogenetic abnormalities according to the IPSS risk criteria showed better overall survival than those with intermediate-risk abnormalities. When analysed according to the IPSS risk classification, high-risk patients had worse survival prospects following decitabine therapy than those with intermediate risk; however, compared to the originally reported IPPS outcomes for high-risk patients, they probably showed better survival. During the treatment period, 18% of the patients progressed towards acute leukaemia. Decitabine showed a rather low toxicity profile in this elderly patient group. In conclusion, low-dose decitabine is an active drug for the treatment of MDS patients, even for those older than 75 years with bad prognostic characteristics.


Myelodysplastic syndrome (MDS) Epigenetic therapy Decitabine Risk factor 

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • P. W. Wijermans
    • 1
  • M. Lübbert
    • 2
  • G. Verhoef
    • 3
  • V. Klimek
    • 4
  • A. Bosly
    • 5
  1. 1.Department of HaematologyLeyenburg HospitalThe HagueThe Netherlands
  2. 2.Department of Medicine, Division of Hematology/OncologyUniversity of Freiburg Medical CentreFreiburgGermany
  3. 3.Department of HematologyUniversity Hospital GasthuisbergLeuvenBelgium
  4. 4.Memorial Sloan-Kettering Cancer CenterNew YorkUSA
  5. 5.Department of HematologyACL Mont-GodinneMont GodinneBelgium

Personalised recommendations